Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Depreciation and Depletion (2018 - 2021)

Endonovo Therapeutics has reported Depreciation and Depletion over the past 6 years, most recently at $1580.0 for Q1 2021.

  • Quarterly results put Depreciation and Depletion at $1580.0 for Q1 2021, down 2.83% from a year ago — trailing twelve months through Dec 2021 was $1580.0 (down 63.55% YoY), and the annual figure for FY2021 was $1580.0, down 63.55%.
  • Depreciation and Depletion for Q1 2021 was $1580.0 at Endonovo Therapeutics, up from $903.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for ENDV hit a ceiling of $1626.0 in Q1 2020 and a floor of $266.0 in Q1 2018.
  • Median Depreciation and Depletion over the past 4 years was $903.0 (2019), compared with a mean of $971.23.
  • Peak annual rise in Depreciation and Depletion hit 180.83% in 2019, while the deepest fall reached 15.99% in 2019.
  • Endonovo Therapeutics' Depreciation and Depletion stood at $1014.0 in 2018, then fell by 10.85% to $904.0 in 2019, then dropped by 0.11% to $903.0 in 2020, then skyrocketed by 74.97% to $1580.0 in 2021.
  • The last three reported values for Depreciation and Depletion were $1580.0 (Q1 2021), $903.0 (Q4 2020), and $903.0 (Q3 2020) per Business Quant data.